Investigating the effectiveness of an online-based program for the treatment of anxiety disorders (Novego) - A randomized controlled trial

Not Applicable

Recruiting

• Conditions: F40.0; F40.01; F40.1; F40.2; F41.0; Agoraphobia; Social phobias; Specific (isolated) phobias; Panic disorder [episodic paroxysmal anxiety]

• Registration Number: DRKS00031668
• Lead Sponsor: IVPNetworks GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 310

Inclusion Criteria

•One of the following diagnoses according to ICD-10 made by specialists or psychotherapists: F40.0x, F40.1, F40.2, F41.0
•Informed consent
•Access to the Internet
•Sufficient knowledge of the German language
•Willingness to participate in three pseudonymized online surveys and willingness to independently use Novego - Ängste überwinden®.
•Patients must be in a stable therapy situation (pharmacotherapy and/or psychotherapy or waiting situation) at least 4 weeks before randomization and should maintain this situation as far as possible during the study period.

Exclusion Criteria

•Presence of a psychotic or bipolar disorder (lifetime)
•Acute suicidal behavior within the last 4 weeks
•Dementia
•Alcohol or substance dependence within the last 6 months
•Current use of highly potent and/or atypical antipsychotics
•Presence of a serious illness which, in the opinion of the investigator, precludes the patient's participation in the study until the end of the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in anxiety symptomatology (sum score) at T1 compared to T0 as measured by the Beck Anxiety Inventory (BAI, Beck et al., 1988)